432 related articles for article (PubMed ID: 24068636)
21. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
22.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
24. Investigation of receptor radionuclide therapy with
Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
[TBL] [Abstract][Full Text] [Related]
25. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
[TBL] [Abstract][Full Text] [Related]
26. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
27. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
28. Initial clinical evaluation of indigenous
Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
[No Abstract] [Full Text] [Related]
29. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
30. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
Davì MV; Bodei L; Ferdeghini M; Falconi M; Testoni M; Paganelli G; Oliani C; Lo Cascio V; Francia G
Endocr Pract; 2008 Mar; 14(2):213-8. PubMed ID: 18308661
[TBL] [Abstract][Full Text] [Related]
31. PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization.
Martí-Climent JM; Prieto E; Elosúa C; Rodríguez-Fraile M; Domínguez-Prado I; Vigil C; García-Velloso MJ; Arbizu J; Peñuelas I; Richter JA
Med Phys; 2014 Sep; 41(9):092503. PubMed ID: 25186412
[TBL] [Abstract][Full Text] [Related]
32. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
33. Tandem peptide receptor radionuclide therapy using
Kunikowska J; Zemczak A; Kołodziej M; Gut P; Łoń I; Pawlak D; Mikołajczak R; Kamiński G; Ruchała M; Kos-Kudła B; Królicki L
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):922-933. PubMed ID: 31980909
[TBL] [Abstract][Full Text] [Related]
34. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
35. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
[TBL] [Abstract][Full Text] [Related]
36. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
37. TeleNEN as a telemedicine model for neuroendocrine neoplasm management in case of Meckel's diverticulum NET.
Kunikowska J; Zemczak A; Górska M; Matyskiel R; Słodkowski M; Łoń I; Chrapko B; Kos-Kudła B; Królicki L
Endokrynol Pol; 2018; 69(3):313-317. PubMed ID: 29952421
[TBL] [Abstract][Full Text] [Related]
38. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
Severi S; Nanni O; Bodei L; Sansovini M; Ianniello A; Nicoletti S; Scarpi E; Matteucci F; Gilardi L; Paganelli G
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with
Sansovini M; Severi S; Ianniello A; Nicolini S; Fantini L; Mezzenga E; Ferroni F; Scarpi E; Monti M; Bongiovanni A; Cingarlini S; Grana CM; Bodei L; Paganelli G
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):490-499. PubMed ID: 27704193
[TBL] [Abstract][Full Text] [Related]
40. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]